Aim About Moles

The main articles are:

• Medical Decision Support Systems (CDS)
• Cancer diagnosis
• Artificial Intelligence in Medicine
• Mobile apps

2023: Obtaining a marketing authorization from Roszdravnazdor

The company AIMED"" resident Skolkovo"" received a registration certificate for the ProRodinka medical decision-making support system neural network. The technology-based service is designed to help a doctor make decisions when diagnosing skin neoplasms from photographs. Skolkovo reported this on December 28, 2023.

The ProRodinki mobile application is 980 thousand images received from 550 thousand users. During the implementation of the project, more than 23 thousand malignant neoplasms were identified, of which almost 14 thousand cases of melanoma.

The software includes several modules of a convolutional neural network, a trained belief system based on diagnostic features of certain pathologies and mathematical calculations. Using the provided images of skin neoplasms, the neural network evaluates and compiles a conclusion comparable to that of a qualified specialist in dermatovenerology and oncology.

Nosologies recognized by the neural network:

• Melanoma;
• BKRK;
• Melanocytic nevus;
• Seborrheic keratosis;
• Hemangioma.

Our resident Aimed received a registration certificate from Roszdravnazdor for a system for supporting medical decisions in dermatology. The neural network of the service allows you to detect all possible types of malignant formations, as well as some other types of skin diseases. Before receiving the marketing authorization, users of the ProRodinki mobile application could use it only to assess the risk of cancer. Obtaining permission from Roszdravnadzor allows medical organizations to purchase software, and doctors to use it when making a diagnosis. We are glad that with the grant and business support of Skolkovo, the team brought its product to the market faster, said Yulia Shcheglova, senior project manager of the Skolkovo biomedical technology cluster.

The service can be used as part of the provision of primary health care, including pre-medical and medical, as well as in a day hospital and at home, as part of the provision of specialized medical care and in scientific activities.

Our product is the result of 5 years of great joint work of doctors and programmers. The built model made it possible to detect melanoma in thousands of people in time. We hope that with obtaining the status of a medical device, we will be able to help people with it in time, in the early stages to detect the disease that has arisen and, thereby, get the possibility of a complete cure. noted Veniamin Dardyk, CEO of AIMED.

The main advantages of this system are:

• Performance - the system can process several hundred thousand images during the working day;
• Efficiency - The system works at the level of a good dermatologist-oncologist. In clinical trials conducted at the Blokhin National Medical Research Center, the system showed a sensitivity of 93.5% with a specificity of 84.3%;
• Availability. If the Internet is available, the system services are available from anywhere in Russia.

The project is being implemented with the support of the Volga Research Medical University (PIMU). The university's team of experts not only acted as the creators of the service, but also organizes promotion in the regions of Russia.

2020: Novartis AI support

AIM, a resident of the Skolkovo Foundation Biomedical Technology Cluster, has signed a one-year contract with Novartis. The Skolkovo Foundation announced this on December 28, 2020. The global pharmaceutical company will support the socially oriented solution "about moles," which allows you to detect malignant skin neoplasms, such as melanoma, using a regular smartphone and artificial intelligence technologies.

The use of solutions based on multifactorial neural networks made it possible to achieve accuracy in the detection of malignant neoplasms at the level of leading oncodermatologists. The technology was developed and tested together with the Volga Research Medical University of the Ministry of Health of Russia, one of the centers for skin oncology in our country. The app for smartphones on Android and iOS platforms is distributed free of charge.

For the first time, the simplicity and availability of a solution for self-examination of skin health makes it possible to conduct revolutionary mass screening of the population with the aim of early detection of skin malignancies. In 2021, with the support of Novartis and the Ministry of Health of the Nizhny Novgorod Region, within the framework of the Region without Melanoma program, we plan to conduct a mass screening of the population. Our solution allows you to reduce the burden on oncodermatologists and make their work more effective in the framework of face-to-face appointments or when using telemedicine products.

At Novartis, we work hard to make the path to early and effective diagnosis of melanoma easier and more convenient and see great potential in partnership with platforms that allow this task to be achieved. After all, if a doctor manages to determine a dangerous disease at the very beginning, this has a positive effect on the result of subsequent therapy. We spend most of our lives online, but this should not interfere with timely care for our health. The project on remote diagnostics "About Moles" gives users the opportunity to take the first step towards a more responsible attitude towards themselves, simply by checking the moles using a smartphone and in case of suspicious signs, consult a doctor.

Timely diagnosis of skin cancer has risen from 71% to 82% in the last 10 years, helping to achieve high efficacy in the treatment of patients with melanoma or basal cell skin cancer. Approximately 90% of patients who were diagnosed in a timely manner and received treatment at an early stage (less than 2 cm, without germination into the underlying tissues) live more than 5 years, which is equivalent to a cure in this nosology. Cooperation of the startup AIMED with the global pharmaceutical company Novartis and the Ministry of Health of the Nizhny Novgorod Region brings the project to a different level. The Skolkovo Foundation's biomedical technology cluster supports developments aimed at early detection of cancer. In this regard, we are very pleased with the success of our participant, who developed an application based on artificial intelligence technologies for the diagnosis of melanoma and basal cell skin cancer. We hope that the project will pass all the stages necessary to introduce this development into real clinical practice.

The solution "About Moles" is included in the case map of the international program "Global Challenge - Artificial Intelligence for Sustainable Development" of the Sk [ai] Hub project.